MedTrace Logo

Brain Vascular and Neurocognitive Health

NCT06497413 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2025-10-06

No results posted yet for this study

Summary

The overall research objective of this proposal is to determine the acute and chronic impact of transcranial photobiomodulation on indices of cerebral vascular health and neurocognitive function.

Conditions

  • Cognitive Decline
  • Cognitive Dysfunction
  • Alzheimer Disease
  • Vascular Disease, Peripheral

Interventions

DEVICE

Transcranial Photobiomodulation

The transcranial photobiomodulation will be delivered through the Neuradiant 1070 Plus-Programmable 4-Quadrant Photobiomodulation System. This is a commercially available helmet that will be purchased from a commercially available source.

DEVICE

Transcranial Photobiomodulation helmet (Neuradiant 1070 Plus) with no light administered

In this condition the participants will wear the Transcranial Photobiomodulation helmet (Neuradiant 1070 Plus); however, the light will not be administered.

Sponsors & Collaborators

  • The University of Texas at Arlington

    lead OTHER

Principal Investigators

  • Robert M Brothers, PhD · University of Texas at Arlington

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-04-16
Primary Completion
2025-08-31
Completion
2025-09-17
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06497413 on ClinicalTrials.gov